MN SF4211

Prohibits prior authorization requirements for atypical antipsychotic drugs prescribed for mental illness treatment if the drug is FDA-approved for that indication, effective January 1, 2023.

Removes prior authorization restrictions for brand-name antipsychotic drugs that have no generic equivalent, were initially prescribed before July 1, 2003, or are part of a recipient's current treatment course.

Grants automatic 60-day prior authorization approval for brand-name mental illness drugs within 60 days of a generic equivalent becoming available if the drug was part of the recipient's treatment at that time.

Requires the commissioner to hold a public forum with 15 days of public comment before implementing prior authorization for any drug, and provide a 15-day notice period before implementation.

Maintains prior authorization and collaborative psychiatric consultation requirements for antipsychotic and ADHD medications in pediatric patients, with exceptions for patients already stabilized on medication or in crisis.